Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7944 results

Sort By:

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Study ID: NCT06513962
Start Date: 2025-02-27
End Date: 2029-10-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

60

Intervention / Treatment

Best Practice

Biospecimen Collection

Electronic Health Record Review

Survey Administration

Triptorelin Pamoate

Sponsor

Children's Oncology Group

Source: clinicaltrials.gov

Share:
Add to list

Epcoritamab in Previously Treated WM

Study ID: NCT06510491
Start Date: 2024-12-06
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

20

Intervention / Treatment

Epcoritamab

Sponsor

Gottfried von Keudell, MD PhD

Source: clinicaltrials.gov

Share:
Add to list

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Study ID: NCT03260491
Start Date: 2017-10-30
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

309

Intervention / Treatment

HER3-DXd (FL-DP)

HER3-DXd (CTM-1 Lyo-DP)

HER3-DXd (CTM-3 Lyo-DP)

Sponsor

First mountain

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Study ID: NCT05593094
Start Date: 2020-10-15
End Date: 2026-10-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

210

Intervention / Treatment

ZN-A-1041 50mg BID

ZN-A-1041 100mg BID

ZN-A-1041 200mg BID

ZN-A-1041 400mg BID

ZN-A-1041 600mg BID

ZN-A-1041 800mg BID

ZN-A-1041 1000mg BID

ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b

ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b

ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b

ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c

ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c

ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c

Sponsor

Suzhou Zanrong Pharma Limited

Source: clinicaltrials.gov

Share:
Add to list

Restoring Metabolic and Reproductive Health With Sleep in PCOS Study, CPAP Trial

Study ID: NCT05920694
Start Date: 2022-12-22
End Date: 2025-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Continuous Positive Airway Pressure Device (CPAP)

Delayed Continuous Positive Airway Pressure Device (CPAP)

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Study ID: NCT06239194
Start Date: 2024-06-12
End Date: 2029-02
Study Type

Interventional

Study Phase

Phase2

No. of Participants

115

Intervention / Treatment

MDX2001

Sponsor

ModeX Therapeutics, An OPKO Health Company

Source: clinicaltrials.gov

Share:
Add to list

Outcomes of Focal Ablation for Prostate Cancer

Study ID: NCT05478694
Start Date: 2023-02-01
End Date: 2026-08
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

225

Intervention / Treatment
Sponsor

University of Texas Southwestern Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Study ID: NCT06031194
Start Date: 2023-05-10
End Date: 2025-11-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Non-Interventional Study

Sponsor

Ohio State University Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Study ID: NCT06173362
Start Date: 2023-11-09
End Date: 2027-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

75

Intervention / Treatment

Abiraterone

Biospecimen Collection

Darolutami

Prednisone

Sponsor

Mamta Parikh

Source: clinicaltrials.gov

Share:
Add to list

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Study ID: NCT04626791
Start Date: 2021-08-03
End Date: 2028-08-03
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Acalabrutib

Bortezomib

Cyclophosphamide

Cytarabine

Doxorubicin Hydrochloride

Prednisone

Rituximab

Rituximab and Hyaluronidase Human

Sponsor

Academic and Community Cancer Research United

Source: clinicaltrials.gov

Share:
Add to list